Clinical relevance and mechanisms of antagonism between the BMP and activin/TGF-β signaling pathways

Journal of the American Osteopathic Association

Volumn 116, Issue 7, 2016, Pages 452-461

  Hudnall, Aaron M ^a   Arthur, Jon W ^a   Lowery, Jonathan W ^a  

^a IN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BONE MORPHOGENETIC PROTEINS; HUMANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84976340226     PISSN: 00986151     EISSN: 19451997     Source Type: Journal    
DOI: 10.7556/jaoa.2016.089     Document Type: Review

References (88)

1. Hinck AP. Structural studies of the TGF-βs and their receptors: insights into evolution of the TGF-βs superfamily. FEBS Lett. 2012;586(14):1860-1870. doi:10.1016/j.febslet.2012.05.028.
2. Gordon KJ, Blobe GC. Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197-228. doi:10.1016/j.bbadis.2008.01.006.
3. Zhang YE. Non-Smad pathways in TGF-β signaling. Cell Res. 2009;19(1):128-139. doi:10.1038/cr.2008.328.
4. Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease. Cytokine Growth Factor Rev. 2010;21(4):287-298. doi:10.1016/j.cytogfr.2010.06.001.
5. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis: where do we go from here? N Engl J Med. 2012;366(22):2048-2051. doi:10.1056/NEJMp1202619.
6. Berasi SP, Varadarajan U, Archambault J, et al. Divergent activities of osteogenic BMP2, and tenogenic BMP12 and BMP13 independent of receptor binding affinities. Growth Factors. 2011;29(4):128-139. doi:10.3109/08977194.2011.593178.
7. Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X. TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol. 2010;12(3):224-234. doi:10.1038/ncb2022.
8. Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010;25(11):2419-2426. doi:10.1002/jbmr.139.
9. Koncarevic A, Cornwall-Brady M, Pullen A, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151(9):4289-4300. doi:10.1210/en.2010-0134.
10. Lotinun S, Pearsall RS, Davies MV, et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone. 2010;46(4):1082-1088. doi:10.1016/j.bone.2010.01.370.
11. Pearsall RS, Canalis E, Cornwall-Brady M, et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci U S A. 2008;105(19):7082-7087. doi:10.1073/pnas.0711263105.
12. Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Min Res. 2009;24(4):744-752. doi:10.1359/jbmr.081208.
13. Fajardo RJ, Manoharan RK, Pearsall RS, et al. Treatment with a soluble receptor for activin improves bone mass and structure in the axial and appendicular skeleton of female cynomolgus macaques (Macaca fascicularis). Bone. 2010;46(1):64-71. doi:10.1016/j.bone.2009.09.018.
14. Tsuji K, Bandyopadhyay A, Harfe BD, et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Gen. 2006;38(12):1424-1429.
15. Zhang F, Qiu T, Wu X, et al. Sustained BMP signaling in osteoblasts stimulates bone formation by promoting angiogenesis and osteoblast differentiation. J Bone Miner Res. 2009;24(7):1224-1233. doi:10.1359/jbmr.090204.
16. Zhao M, Harris SE, Horn D, et al. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation. J Cell Biol. 2002;157(6):1049-1060.
17. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242(4885):1528-1534.
18. Hiraki Y, Inoue H, Shigeno C, et al. Bone morphogenetic proteins (BMP-2 and BMP-3) promote growth and expression of the differentiated phenotype of rabbit chondrocytes and osteoblastic MC3T3-E1 cells in vitro. J Bone Miner Res. 1991;6(12):1373-1385.
19. Yamaguchi A, Katagiri T, Ikeda T, et al. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol. 1991;113(3):681-687.
20. Chen P, Carrington JL, Hammonds RG, Reddi AH. Stimulation of chondrogenesis in limb bud mesoderm cells by recombinant human bone morphogenetic protein 2B (BMP-2B) and modulation by transforming growth factor β 1 and β 2. Exp Cell Res. 1991;195(2):509-515.
21. Asahina I, Sampath TK, Nishimura I, Hauschka PV. Human osteogenic protein-1 induces both chondroblastic and osteoblastic differentiation of osteoprogenitor cells derived from newborn rat calvaria. J Cell Biol. 1993;123(4):921-933.
22. Schindeler A, Morse A, Peacock L, et al. Rapid cell culture and pre-clinical screening of a transforming growth factor-β (TGF-β) inhibitor for orthopaedics. BMC Musculoskelet Disord. 2010;11:105. doi:10.1186/1471-2474-11-105.
23. de Jong DS, van Zoelen EJ, Bauerschmidt S, Olijve W, Steegenga WT. Microarray analysis of bone morphogenetic protein, transforming growth factor β, and activin early response genes during osteoblastic cell differentiation. J Bone Miner Res. 2002;17(12):2119-2129.
24. Kawamura I, Maeda S, Imamura K, et al. SnoN suppresses maturation of chondrocytes by mediating signal cross-talk between transforming growth factor-β and bone morphogenetic protein pathways. J Biol Chem. 2012;287(34):29101-29113. doi:10.1074/jbc.M112.349415.
25. Hanada K, Solchaga LA, Caplan AI, et al. BMP-2 induction and TGF-β 1 modulation of rat periosteal cell chondrogenesis. J Cell Biochem. 2001;81(2):284-294.
26. Dieudonne SC, Semeins CM, Goei SW, et al. Opposite effects of osteogenic protein and transforming growth factor β on chondrogenesis in cultured long bone rudiments. J Bone Miner Res. 1994;9(6):771-780.
27. Cheifetz S, Li IW, McCulloch CA, Sampath K, Sodek J. Influence of osteogenic protein-1 (OP-1;BMP-7) and transforming growth factor-β 1 on bone formation in vitro. Connect Tissue Res. 1996;35(1-4):71-78.
28. Li TF, Darowish M, Zuscik MJ, et al. Smad3-deficient chondrocytes have enhanced BMP signaling and accelerated differentiation. J Bone Miner Res. 2006;21(1):4-16.
29. Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem. 1999;75(2):206-214.
30. Woeckel VJ, van der Eerden BC, Schreuders-Koedam M, Eijken M, Van Leeuwen JP. 1α,25-dihydroxyvitamin D3 stimulates activin A production to fine-tune osteoblast-induced mineralization. J Cell Physiol. 2013;228(11):2167-2174. doi:10.1002/jcp.24388.
31. Alves RD, Eijken M, Bezstarosti K, Demmers JA, van Leeuwen JP. Activin A suppresses osteoblast mineralization capacity by altering extracellular matrix (ECM) composition and impairing matrix vesicle (MV) production. Mol Cell Proteomics. 2013;12(10):2890-2900. doi:10.1074/mcp.M112.024927.
32. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129-133.
33. Cadena SM, Tomkinson KN, Monnell TE, et al. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type. J Appl Physiol (1985). 2010;109(3):635-642. doi:10.1152/japplphysiol.00866.2009.
34. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A. 2005;102(50):18117-18122.
35. Sartori R, Schirwis E, Blaauw B, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45(11):1309-1318. doi:10.1038/ng.2772.
36. Winbanks CE, Chen JL, Qian H, et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol. 2013;203(2):345-357. doi:10.1083/jcb.201211134.
37. Yndestad A, Larsen KO, Oie E, et al. Elevated levels of activin A in clinical and experimental pulmonary hypertension. J Appl Physiol (1985). 2009;106(4):1356-1364. doi:10.1152/japplphysiol.90719.2008.
38. Bazan IS, Fares WH. Pulmonary hypertension: diagnostic and therapeutic challenges. Ther Clin Risk Manag. 2015;11:1221-1233. doi:10.2147/TCRM.S74881.
39. Ma W, Han W, Greer PA, et al. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest. 2011;121(11):4548-4566. doi:10.1172/JCI57734.
40. Graham BB, Chabon J, Gebreab L, et al. Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation. 2013;128(12):1354-1364. doi:10.1161/CIRCULATIONAHA.113.003072.
41. Megalou AJ, Glava C, Vilaeti AD, et al. Transforming growth factor-β inhibition and endothelin receptor blockade in rats with monocrotaline-induced pulmonary hypertension. Pulm Circ. 2012;2(4):461-469. doi:10.4103/2045-8932.105034.
42. Davies RJ, Holmes AM, Deighton J, et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-β in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol. 2012;302(6):L604-L615. doi:10.1152/ajplung.00309.2011.
43. Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med. 2015;21(7):777-785. doi:10.1038/nm.3877.
44. Cutroneo KR. TGF-β-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen. 2007;15(suppl 1):S54-S60. doi:10.1111/j.1524-475X.2007.00226.x.
45. Piersma B, Bank RA, Boersema M. Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med (Lausanne). 2015;2:59. doi:10.3389/fmed.2015.00059.
46. Wang S, Sun A, Li L, et al. Up-regulation of BMP-2 antagonizes TGF-β1/ROCK-enhanced cardiac fibrotic signalling through activation of Smurf1/Smad6 complex. J Cell Mol Med. 2012;16(10):2301-2310. doi:10.1111/j.1582-4934.2012.01538.x.
47. Saika S, Ikeda K, Yamanaka O, et al. Adenoviral gene transfer of BMP-7, Id2, or Id3 suppresses injury-induced epithelial-to-mesenchymal transition of lens epithelium in mice. Am J Physiol Cell Physiol. 2006;290(1):C282-C289.
48. Yang G, Zhu Z, Wang Y, Gao A, Niu P, Tian L. Bone morphogenetic protein-7 inhibits silica-induced pulmonary fibrosis in rats. Toxicol Lett. 2013;220(2):103-108. doi:10.1016/j.toxlet.2013.04.017.
49. Stumm CL, Halcsik E, Landgraf RG, Camara NO, Sogayar MC, Jancar S. Lung remodeling in a mouse model of asthma involves a balance between TGF-β1 and BMP-7. PloS One. 2014;9(4):e95959. doi:10.1371/journal.pone.0095959.
50. Manson SR, Niederhoff RA, Hruska KA, Austin PF. Endogenous BMP-7 is a critical molecular determinant of the reversibility of obstruction-induced renal injuries. Am J Physiol Renal Physiol. 2011;301(6):F1293-F12302. doi:10.1152/ajprenal.00071.2011.
51. Yamamoto M, Beppu H, Takaoka K, et al. Antagonism between Smad1 and Smad2 signaling determines the site of distal visceral endoderm formation in the mouse embryo. J Cell Biol. 2009;184(2):323-334. doi:10.1083/jcb.200808044.
52. Jiang FX, Stanley EG, Gonez LJ, Harrison LC. Bone morphogenetic proteins promote development of fetal pancreas epithelial colonies containing insulin-positive cells. J Cell Sci. 2002;115(pt 4):753-760.
53. Cabrera-Sharp V, Read JE, Richardson S, et al. SMAD1/5 signaling in the early equine placenta regulates trophoblast differentiation and chorionic gonadotropin secretion. Endocrinology. 2014;155(8):3054-3064. doi:10.1210/en.2013-2116.
54. Oshimori N, Fuchs E. Paracrine TGF-β signaling counterbalances BMP-mediated repression in hair follicle stem cell activation. Cell Stem Cell. 2012;10(1):63-75. doi:10.1016/j.stem.2011.11.005.
55. Robson NC, Hidalgo L, McAlpine T, et al. Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling. Cancer Res. 2014;74(18): 5019-5031. doi:10.1158/0008-5472.CAN-13-2845.
56. Meurer SK, Esser M, Tihaa L, Weiskirchen R. BMP-7/TGF-β1 signalling in myoblasts: components involved in signalling and BMP-7-dependent blockage of TGF-β-mediated CTGF expression. Eur J Cell Biol. 2012;91(6-7):450-463. doi:10.1016/j.ejcb.2011.09.004.
57. Sudheer S, Bhushan R, Fauler B, Lehrach H, Adjaye J. FGF inhibition directs BMP4-mediated differentiation of human embryonic stem cells to syncytiotrophoblast. Stem Cells Dev. 2012;21(16):2987-3000. doi:10.1089/scd.2012.0099.
58. Erb TM, Schneider C, Mucko SE, et al. Paracrine and epigenetic control of trophectoderm differentiation from human embryonic stem cells: the role of bone morphogenic protein 4 and histone deacetylases. Stem Cells Dev. 2011;20(9):1601-1614. doi:10.1089/scd.2010.0281.
59. Quarto N, Li S, Renda A, Longaker MT. Exogenous activation of BMP-2 signaling overcomes TGFβ-mediated inhibition of osteogenesis in Marfan embryonic stem cells and Marfan patient-specific induced pluripotent stem cells. Stem Cells. 2012;30(12):2709-2719. doi:10.1002/stem.1250.
60. Star GP, Giovinazzo M, Langleben D. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvasc Res. 2013;85:46-53. doi:10.1016/j.mvr.2012.10.012.
61. Fuchshofer R, Stephan DA, Russell P, Tamm ER. Gene expression profiling of TGFβ2- and/or BMP7-treated trabecular meshwork cells: identification of Smad7 as a critical inhibitor of TGF-β2 signaling. Exp Eye Res. 2009;88(6):1020-1032. doi:10.1016/j.exer.2009.01.002.
62. Luo DD, Phillips A, Fraser D. Bone morphogenetic protein-7 inhibits proximal tubular epithelial cell Smad3 signaling via increased SnoN expression. Am J Pathol. 2010;176(3):1139-1147. doi:10.2353/ajpath.2010.090459.
63. Candia AF, Watabe T, Hawley SH, et al. Cellular interpretation of multiple TGF-β signals: intracellular antagonism between activin/BVg1 and BMP-2/4 signaling mediated by Smads. Development. 1997;124(22):4467-4480.
64. Veerasamy M, Phanish M, Dockrell ME. Smad mediated regulation of inhibitor of DNA binding 2 and its role in phenotypic maintenance of human renal proximal tubule epithelial cells. PLoS One. 2013;8(1):e51842. doi:10.1371/journal.pone.0051842.
65. Massague J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630.
66. Ling MT, Wang X, Tsao SW, Wong YC. Down-regulation of Id-1 expression is associated with TGFβ1-induced growth arrest in prostate epithelial cells. Biochim Biophys Acta. 2002;1570(3):145-152.
67. Liang YY, Brunicardi FC, Lin X. Smad3 mediates immediate early induction of Id1 by TGF-β. Cell Res. 2009;19(1):140-148. doi:10.1038/cr.2008.321.
68. Piek E, Afrakhte M, Sampath K, van Zoelen EJ, Heldin CH, ten Dijke P. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J Cell Physiol. 1999;180(2):141-149.
69. Galvin KE, Travis ED, Yee D, Magnuson T, Vivian JL. Nodal signaling regulates the bone morphogenic protein pluripotency pathway in mouse embryonic stem cells. J Biol Chem. 2010;285(26):19747-19756. doi:10.1074/jbc.M109.077347.
70. Ehnert S, Zhao J, Pscherer S, et al. Transforming growth factor β1 inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): possible mechanism for the failure of BMP therapy? BMC Med. 2012;10:101. doi:10.1186/1741-7015-10-101.
71. Sugimoto H, LeBleu VS, Bosukonda D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med. 2012;18(3):396-404. doi:10.1038/nm.2629.
72. Nakamura M, Matzuk MM, Gerstmayer B, et al. Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin. FASEB J. 2003;17(3):497-499.
73. Harris SE, Bonewald LF, Harris MA, et al. Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res. 1994;9(6):855-863.
74. Denecke B, Wickert L, Liu Y, Ciuclan L, Dooley S, Meindl-Beinker NM. Smad7 dependent expression signature highlights BMP2 and HK2 signaling in HSC transdifferentiation. World J Gastroenterol. 2010;16(41):5211-5224.
75. Yang YL, Liu YS, Chuang LY, et al. Bone morphogenetic protein-2 antagonizes renal interstitial fibrosis by promoting catabolism of type I transforming growth factor-β receptors. Endocrinology. 2009;150(2):727-740. doi:10.1210/en.2008-0090.
76. Izumi N, Mizuguchi S, Inagaki Y, et al. BMP-7 opposes TGF-β1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L120-L126.
77. Zode GS, Clark AF, Wordinger RJ. Bone morphogenetic protein 4 inhibits TGF-β2 stimulation of extracellular matrix proteins in optic nerve head cells: role of gremlin in ECM modulation. Glia. 2009;57(7):755-766. doi:10.1002/glia.20803.
78. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol. 2008;19(11):2098-2107. doi:10.1681/ASN.2007111261.
79. Lowery JW, Intini G, Gamer L, et al. Loss of BMPR2 leads to high bone mass due to increased osteoblast activity. J Cell Sci. 2015;128(7):1308-1315. doi:10.1242/jcs.156737.
80. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, Attisano L. Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis. Mol Cell Biol. 2003;23(20):7230-7242.
81. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672-1678.
82. Upton PD, Davies RJ, Tajsic T, Morrell NW. Transforming growth factor-β(1) represses bone morphogenetic protein-mediated Smad signaling in pulmonary artery smooth muscle cells via Smad3. Am J Respir Cell Mol Biol. 2013;49(6):1135-1145. doi:10.1165/rcmb.2012-0470OC.
83. Han C, Hong KH, Kim YH, et al. SMAD1 deficiency in either endothelial or smooth muscle cells can predispose mice to pulmonary hypertension. Hypertension. 2013;61(5):1044-1052. doi:10.1161/HYPERTENSIONAHA.111.199158.
84. Ogo T, Chowdhury HM, Yang J, et al. Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013;48(6):733-741. doi:10.1165/rcmb.2012-0049OC.
85. Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J. 2012;39(2):329-343. doi:10.1183/09031936.00187310.
86. Guemes M, Garcia AJ, Rigueur D, et al. GATA4 is essential for bone mineralization via ERalpha and TGFβ/BMP pathways. J Bone Miner Res. 2014;29(12):2676-2687. doi:10.1002/jbmr.2296.
87. Lin J, Patel SR, Wang M, Dressler GR. The cysteine-rich domain protein KCP is a suppressor of transforming growth factor β/activin signaling in renal epithelia. Mol Cell Biol. 2006;26(12):4577-4585.
88. Gronroos E, Kingston IJ, Ramachandran A, Randall RA, Vizan P, Hill CS. Transforming growth factor β inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes. Mol Cell Biol. 2012;32(14):2904-2916. doi:10.1128/MCB.00231-12.